1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Brava: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer Nivolumab 40 mg in 4 ml Injection, Ipilimumab 200 MG in 40 ML Injection, Chemoradiation - Uterine Cervical Neoplasms | Phase 2 | Recruiting | Hospital Israelita Albert Einstein | 112 | 2022-08-30 | 2024-01-05 |
Uterine Cervical Neoplasms (1)
Chemoradiotherapy (1) · Injections (1) · Ipilimumab (1) · Nivolumab (1)
Brazil (1)